About Biovalence Technologies
-
May 26, 2020
2011
Founding of company, Biovalence Sdn Bhd
-
May 26, 2020
2013
US patent granted for “Antimicrobial Fusion Compound And Uses Thereof” by Abu Bakar Awang et al. US Patent Publication No. 2013/0336955 A1.
-
May 26, 2020
2014
Publication of Discovery Paper in PLOS ONE demonstrating the proof of concept of Biovalence Technologies recombinant proteomics technology against all 4 serotypes of the Dengue virus (Flaviviridae)
-
May 26, 2020
2014
Finalist at BioPharma 2014 showcasing the broad-spectrum antiviral activity of the world’s first genetically-designed antiviral proteins
-
May 26, 2020
2016
One of 4 recipients awarded for the Dengue Tech Challenge 2016 by the University of Cambridge, UK: https://www.britishcouncil.my/programmes/newton-ungku-omar-fund/dengue-tech-challenge-2016
-
May 26, 2020
Apr 2017
Finalist at BioPharma 2017 showcasing the pre-clinical studies of RetroMAD1, one of the 4 genetically-designed antiviral proteins
-
May 26, 2020
Aug 2017
Acquired by Singaporean angel investors and establishment of a Corporate HQs, Biovalence Technologies Pte Ltd, in Singapore for the purpose of attracting investors and commercialisation of RetroMAD1
-
May 26, 2020
Dec 2019
Publication of landmark field trial on RetroMAD1 in the treatment of feline leukaemia (Retroviridae) by the Federal University of Rio de Janeiro, Brazil
-
May 26, 2020
Mar 2020
The company is in the news with its commentary on the possible application of RetroMAD1 for Covid-19: https://www.scmp.com/news/asia/southeast-asia/article/3075604/coronavirus-singapore-start-thinks-cat-leukaemia-drug
-
May 26, 2020
Apr 2020
Pre-series A investment valuing the company at US$ 20 million
-
May 26, 2020
Apr 2020
Launch of e-commerce website, www.retromad1.com, for the US$16 billion pet therapeutics market